Evolutionary modeling of rate shifts reveals specificity determinants in HIV-1 subtypes

PLoS Computational Biology

Volumn 4, Issue 11, 2008, Pages

  Penn, Osnat ^a   Stern, Adi ^a   Rubinstein, Nimrod D ^a   Dutheil, Julien ^b   Bacharach, Eran ^a   Galtier, Nicolas ^c   Pupko, Tal ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b AARHUS UNIVERSITY   (Denmark)

^c INSTITUT DES SCIENCES DE L EVOLUTION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; DRUG THERAPY; LIFE CYCLE; STATISTICAL TESTS; VIRUSES;

ALTERNATIVE HYPOTHESIS; BAYESIAN METHODS; EVOLUTIONARY MODELS; FUNCTIONAL CONSTRAINTS; HUMAN IMMUNODEFICIENCY VIRUS-1; MOST LIKELY; RANDOM SUBSTITUTION; RAPID RATE; SITE-SPECIFIC; SPECIFIC SITES;

BAYESIAN NETWORKS;

PROTEOME;

ARTICLE; BAYES THEOREM; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR EVOLUTION; PHYLOGENY; ADAPTATION; AMINO ACID SEQUENCE; BIOLOGICAL MODEL; GENETICS; GEOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY; PHYSIOLOGY; PROTEOMICS; SPECIES DIFFERENTIATION; TIME; VIRUS ENTRY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADAPTATION, BIOLOGICAL; AMINO ACID SEQUENCE; BAYES THEOREM; DRUG RESISTANCE, MULTIPLE, VIRAL; EVOLUTION, MOLECULAR; GENETIC SPECIATION; GEOGRAPHY; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; PHYLOGENY; PROTEOMICS; TIME FACTORS; VIRUS INTERNALIZATION;

EID: 57149084079     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1000214     Document Type: Article

References (79)

1. Wainberg MA (2004) HIV-1 subtype distribution and the problem of drug resistance. AIDS 18(Suppl 3): S63-S68.
2. Simon F, Mauclere P, Roques P, Loussert-Ajaka I, Muller-Trutwin MC, et al. (1998) Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med 4: 1032-1037.
3. Julg B, Goebel FD (2005) HIV genetic diversity: any implications for drug resistance? Infection 33: 299-301.
4. Korber B, Gifford A, Myers G (1993) Patterns of variation among international isolates in the highly immunogenic V3 region of the HIV-1 envelope protein. AIDS Res Hum Retroviruses 9(Suppl 1): S98.
5. Gao F, Robertson DL, Carruthers CD, Morrison SG, Jian B, et al. (1998) A comprehensive panel of near-full-length clones and reference sequences for nonsubtype B isolates of human immunodeficiency virus type 1. J Virol 72: 5680-5698.
6. Travers SA, O'Connell MJ, McCormack GP, McInerney JO (2005) Evidence for heterogeneous selective pressures in the evolution of the env gene in different human immunodeficiency virus type 1 subtypes. J Virol 79: 1836-1841.
7. Guindon S, Rodrigo AG, Dyer KA, Huelsenbeck JP (2004) Modeling the site-specific variation of selection patterns along lineages. Proc Natl Acad Sci U S A 101: 12957-12962.
8. Kosakovsky Pond SL, Frost SDW, Grossman Z, Gravenor MB, Richman DD, et al. (2006) Adaptation to different human populations by HIV-1 revealed by codon-based analyses. PLoS Comput Biol 2: e62. doi:10.1371/journal.pcbi.0020062.
9. Shafer RW, Eisen JA, Merigan TC, Katzenstein DA (1997) Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J Virol 71: 5441-5448.
10. Fares MA, Travers SA (2006) A novel method for detecting intramolecular coevolution: adding a further dimension to selective constraints analyses. Genetics 173: 9-23.
11. Ranga U, Shankarappa R, Siddappa NB, Ramakrishna L, Nagendran R, et al. (2004) Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J Virol 78: 2586-2590.
12. Bannister WP, Ruiz L, Loveday C, Vella S, Zilmer K, et al. (2006) HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir Ther 11: 707-715.
13. Bocket L, Cheret A, Deuffic-Burban S, Choisy P, Gerard Y, et al. (2005) Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir Ther 10: 247-254.
14. Alexander CS, Montessori V, Wynhoven B, Dong W, Chan K, et al. (2002) Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antivir Ther 7: 31-35.
15. Pillay D, Walker AS, Gibb DM, de Rossi A, Kaye S, et al. (2002) Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis 186: 617-625.
16. Kimura M (1983) Neutral Theory of Molecular Evolution. New York: Cambridge University Press.
17. Knudsen B, Miyamoto MM (2001) A likelihood ratio test for evolutionary rate shifts and functional divergence among proteins. Proc Natl Acad Sci U S A 98: 14512-14517.
18. Gu X (1999) Statistical methods for testing functional divergence after gene duplication. Mol Biol Evol 16: 1664-1674.
19. Gaucher EA, Miyamoto MM, Benner SA (2001) Function-structure analysis of proteins using covarion-based evolutionary approaches: elongation factors. Proc Natl Acad Sci U S A 98: 548-552.
20. Wang Y, Gu X (2001) Functional divergence in the caspase gene family and altered functional constraints: statistical analysis and prediction. Genetics 158: 1311-1320.
21. Moreira D, Le Guyader H, Philippe H (1999) Unusually high evolutionary rate of the elongation factor 1 alpha genes from the Ciliophora and its impact on the phylogeny of eukaryotes. Mol Biol Evol 16: 234-245.
22. Abhiman S, Sonnhammer EL (2005) Large-scale prediction of function shift in protein families with a focus on enzymatic function. Proteins 60: 758-768.
23. Pupko T, Galtier N (2002) A covarion-based method for detecting molecular adaptation: application to the evolution of primate mitochondrial genomes. Proc Biol Sci 269: 1313-1316.
24. Lopez P, Casane D, Philippe H (2002) Heterotachy, an important process of protein evolution. Mol Biol Evol 19: 1-7.
25. Galtier N (2001) Maximum-likelihood phylogenetic analysis under a covarion-like model. Mol Biol Evol 18: 866-873.
26. Yang Z, Nielsen R (2002) Codon-substitution models for detecting molecular adaptation at individual sites along specific lineages. Mol Biol Evol 19: 908-917.
27. Zhang J, Nielsen R, Yang Z (2005) Evaluation of an improved branch-site likelihood method for detecting positive selection at the molecular level. Mol Biol Evol 22: 2472-2479.
28. Gu X (2001) Maximum-likelihood approach for gene family evolution under functional divergence. Mol Biol Evol 18: 453-464.
29. Gu X, Fu YX, Li WH (1995) Maximum likelihood estimation of the heterogeneity of substitution rate among nucleotide sites. Mol Biol Evol 12: 546-557.
30. Blouin C, Boucher Y, Roger AJ (2003) Inferring functional constraints and divergence in protein families using 3D mapping of phylogenetic information. Nucleic Acids Res 31: 790-797.
31. Dorman KS (2007) Identifying dramatic selection shifts in phylogenetic trees. BMC Evol Biol 7(Suppl 1): S10.
32. Nei M, Rogozin IB, Piontkivska H (2000) Purifying selection and birth-and-death evolution in the ubiquitin gene family. Proc Natl Acad Sci U S A 97: 10866-10871.
33. Mayrose I, Doron-Faigenboim A, Bacharach E, Pupko T (2007) Towards realistic codon models: among site variability and dependency of synonymous and non-synonymous rates. Bioinformatics 23: i319-i327.
34. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242.
35. Lukashov VV, Huismans R, Rakhmanova AG, Lisitsina ZN, Akhtyrskaya NA, et al. (1999) Circulation of subtype A and gagA/envB recombinant HIV type 1 strains among injecting drug users in St. Petersburg, Russia, correlates with geographical origin of infections. AIDS Res Hum Retroviruses 15: 1577-1583.
36. Carr JK, Zarandia M, Tsertsvadze T (2001) Distinctive subtype A HIV-1 in the former Soviet Union displays little diversity after six years of extensive geographic spread among IDU [abstract 197]. Program and abstracts of the 8th Conference on Retrovirus and Opportunistic Infections (Chicago) Alexandria, VA: Foundation for Retrovirology and Human Health 99.
37. Novitsky VA, Montano MA, Essex M (1998) Molecular epidemiology of an HIV-1 subtype A subcluster among injection drug users in the Southern Ukraine. AIDS Res Hum Retroviruses 14: 1079-1085.
38. Bobkov A, Cheingsong-Popov R, Selimova L, Ladnaya N, Kazennova E, et al. (1997) An HIV type 1 epidemic among injecting drug users in the former Soviet Union caused by a homogeneous subtype A strain. AIDS Res Hum Retroviruses 13: 1195-1201.
39. Thomson MM, de Parga EV, Vinogradova A, Sierra M, Yakovlev A, et al. (2007) New insights into the origin of the HIV type 1 subtype A epidemic in former soviet union's countries derived from sequence analyses of preepidemically transmitted viruses. AIDS Res Hum Retroviruses 23: 1599-1604.
40. Arvieux C, Tribut O (2005) Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. Drugs 65: 633-659.
41. Rusconi S, La Seta Catamancio S, Citterio P, Kurtagic S, Violin M, et al. (2000) Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother 44: 1328-1332.
42. Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, et al. (2006) Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 14: 125-130.
43. Bohnlein E, Berger J, Hauber J (1991) Functional mapping of the human immunodeficiency virus type 1 Rev RNA binding domain: new insights into the domain structure of Rev and Rex. J Virol 65: 7051-7055.
44. Pollard VW, Malim MH (1998) The HIV-1 Rev protein. Annu Rev Microbiol 52: 491-532.
45. Novembre J, Galvani AP, Slatkin M (2005) The geographic spread of the CCR5 Δ32 HIV-resistance allele. PLoS Biol 3: e339. doi:10.1371/journal. pbio.0030339.
46. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, et al. (1998) A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280: 1949-1953.
47. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, et al. (2000) HIV-1 nomenclature proposal. Science 288: 55-56.
48. Middleton D, Williams F, Meenagh A, Daar AS, Gorodezky C, et al. (2000) Analysis of the distribution of HLA-A alleles in populations from five continents. Hum Immunol 61: 1048-1052.
49. Williams F, Meenagh A, Darke C, Acosta A, Daar AS, et al. (2001) Analysis of the distribution of HLA-B alleles in populations from five continents. Hum Immunol 62: 645-650.
50. Moore CB, John M, James IR, Christiansen FT, Witt CS, et al. (2002) Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296: 1439-1443.
51. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, et al. (2001) Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412: 334-338.
52. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, et al. (2004) HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10: 282-289.
53. Bhattacharya T, Daniels M, Heckerman D, Foley B, Frahm N, et al. (2007) Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 315: 1583-1586.
54. Liu Y, McNevin J, Zhao H, Tebit DM, Troyer RM, et al. (2007) Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape. J Virol 81: 12179-12188.
55. Fitch WM (1971) Toward defining the course of evolution: minimum change for a specific tree topology. Syst Zool 20: 406-416.
56. Swofford DL, Olsen GJ, Waddell PJ, Hillis DM (1996) Phylogenetic inference. In: Hillis DM, Mable BK, eds. Molecular Systematics. 2nd ed. Sunderland (Massachusetts): Sinauer Associates. pp 407-514.
57. Yang Z (1996) Among-site variation and its impact on phylogenetic analyses. Trends Ecol Evol 11: 367-372.
58. Yang Z (1994) Maximum likelihood phylogenetic estimation from DNA sequences with variable rates over sites: approximate methods. J Mol Evol 39: 306-314.
59. Abascal F, Zardoya R, Posada D (2005) ProtTest: selection of best-fit models of protein evolution. Bioinformatics 21: 2104-2105.
60. Nickle DC, Heath L, Jensen MA, Gilbert PB, Mullins JI, et al. (2007) HIV-specific probabilistic models of protein evolution. PLoS ONE 2: e503. doi:10.1371/journal.pone.0000503.
61. Yang Z, Nielsen R, Goldman N, Pedersen AM (2000) Codon-substitution models for heterogeneous selection pressure at amino acid sites. Genetics 155: 431-449.
62. Felsenstein J (1981) Evolutionary trees from DNA sequences: a maximum likelihood approach. J Mol Evol 17: 368-376.
63. Self SG, Liang KY (1987) Asymptotic properties of maximum likelihood estimators and likelihood ratio tests under nonstandard conditions. J Am Stat Assoc 82: 605-610.
64. Dutheil J, Pupko T, Jean-Marie A, Galtier N (2005) A model-based approach for detecting coevolving positions in a molecule. Mol Biol Evol 22: 1919-1928.
65. Pupko T, Pe'er I, Shamir R, Graur D (2000) A fast algorithm for joint reconstruction of ancestral amino acid sequences. Mol Biol Evol 17: 890-896.
66. Jones DT, Taylor WR, Thornton JM (1992) The rapid generation of mutation data matrices from protein sequences. Comput Appl Biosci 8: 275-282.
67. Tsodikov OV, Record MT Jr, Sergeev YV (2002) Novel computer program for fast exact calculation of accessible and molecular surface areas and average surface curvature. J Comput Chem 23: 600-609.
68. Miller S, Janin J, Lesk AM, Chothia C (1987) Interior and surface of monomeric proteins. J Mol Biol 196: 641-656.
69. Kabsch W, Sander C (1983) Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22: 2577-2637.
70. McGuire G, Wright F, Prentice MJ (1997) A graphical method for detecting recombination in phylogenetic data sets. Mol Biol Evol 14: 1125-1131.
71. Loytynoja A, Goldman N (2008) Phylogeny-aware gap placement prevents errors in sequence alignment and evolutionary analysis. Science 320: 1632-1635.
72. Guindon S, Lethiec F, Duroux P, Gascuel O (2005) PHYML Online - a web server for fast maximum likelihood-based phylogenetic inference. Nucleic Acids Res 33: W557-W559.
73. Lum JJ, Cohen OJ, Nie Z, Weaver JG, Gomez TS, et al. (2003) Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest 111: 1547-1554.
74. Gatanaga H, Suzuki Y, Tsang H, Yoshimura K, Kavlick MF, et al. (2002) Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J Biol Chem 277: 5952-5961.
75. VerPlank L, Bouamr F, LaGrassa TJ, Agresta B, Kikonyogo A, et al. (2001) Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Natl Acad Sci U S A 98: 7724-7729.
76. Accola MA, Bukovsky AA, Jones MS, Gottlinger HG (1999) A conserved dileucine-containing motif in p6(gag) governs the particle association of Vpx and Vpr of simian immunodeficiency viruses SIV(mac) and SIV(agm). J Virol 73: 9992-9999.
77. Svicher V, Ceccherini-Silberstein F, Erba F, Santoro M, Gori C, et al. (2005) Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. Antimicrob Agents Chemother 49: 2015-2025.
78. Wang WK, Dudek T, Essex M, Lee TH (1999) Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. Proc Natl Acad Sci U S A 96: 4558-4562.
79. Kliger Y, Peisajovich SG, Blumenthal R, Shai Y (2000) Membrane-induced conformational change during the activation of HIV-1 gp41. J Mol Biol 301: 905-914.